How much revenue does Guanhao Biotech make?

Guanhao Biotech reported 387.75 million CNY in revenue for fiscal year 2025, up 2.7% from 377.48 million CNY in fiscal year 2024. In Q1 2026 revenue was 93.44 million CNY.

What companies are similar to Guanhao Biotech?

Listed companies of a similar size in the same industry (targeted healthcare equipment) include Guangdong Biolight Meditech Co., Ltd. (300246.SZ), Ningbo David Medical Device Co., Ltd. (300314.SZ), Medprin Regenerative Medical Technologies Co., Ltd. (301033.SZ), Nanjing Medlander Medical Technology Co.,Ltd. (688273.SS).

Guanhao Biotech Co.,Ltd. (300238.SZ) Stock

About Guanhao Biotech Co.,Ltd.

Guanhao Biotech Co.,Ltd. develops, manufactures, and sells regenerative medicines and life sciences products in China. It offers NormalGEN and GrandNeuro, both a dura repair patch; ThormalGEN, a surgical patch; DermalGEN, a wound dressing product; IREAL breast patch; and Youvision corneal graft, as well as license in intraocular lenses. The company also provides Biological dura, a spinal patch; Ty...

At a glance

Guanhao Biotech reported revenue of 387.75 million CNY for fiscal year 2025, up 2.7% from fiscal year 2024, and net income of 24.35 million CNY. In Q1 2026 (the quarter ended March 31, 2026) revenue was 93.44 million CNY, down 1.4% from a year before.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.